Pierre-Alain SchiebProfessor, Chair of Industrial Bioeconomy - NEOMA Business School
Dr. Pierre-Alain Schieb (a French national) is President of Backcasting SAS and Professor, Chair of Industrial Bioeconomy, NEOMA Business School (Reims).
Until April 30, 2013, he was Counsellor in the Directorate of Science, Technology and Industry of the OECD, which manages the International Futures Programme, the OECD’s strategic foresight unit. He was in charge of the International Futures Network, and Head of OECD Futures Projects, such as the projects on Future Global Shocks, Infrastructure Needs to 2030/2050, The Family to 2030, Bioeconomy 2030. Further to recommendations arising from a two year Futures Project, Dr. Schieb was also in charge of the OECD Forum on Space Economics. He was also the Chairman of the Technical Committee on Space Economy of the International Astronautical Federation.
Before joining the OECD in 1994, Dr. Schieb was Executive Vice-President of International Business of one France’s major retailing groups (1991-1994); Dean of a graduate school of business in France (1985-1991); and held an Associate-Professorship at the University of Paris, Dauphine.
Co-founder of a high-tech start-up company in the early 1980s and involved in venture capital initiatives, Dr. Schieb was also a consultant to numerous French and US companies in the field of alliances, industrial cooperation, licensing, corporate and marketing strategies. He has also published many articles in the field of international management, risk management, marketing and corporate strategy.
Dr. Schieb earned a PhD (Doctorat d’Etat) in management science from the University of Strasbourg (1981), a DBA in economics and business administration from the University of Aix-en-Provence (1974), and a MSc in quantitative marketing from the University of Sherbrooke (Canada). Dr. Schieb has received numerous distinctions such as: the Best Award in Economy (Aix-en-Provence, 1967), Best Dissertation Award (Quebec, Canada, 1974), Chevalier in the French Order of Palmes Académiques (1991).
How to Measure Progress? An OECD perspective
The OECD report, Bioeconomy to 2030: designing a policy agenda, 2009, has recognized the industrial bioeconomy as one of the most promising pillars of the potential bioeconomy with 39% of total gross value added expected in the OECD area by 2030.
Measuring progress of the industrial bioeconomy from an OECD perspective would require one pre-requisite, three main segments of statistics to be measured consistently and a number of technicalities.
The pre-requisite is that definitions and indicators about the industrial bioeconomy be internationally or at least multilaterally agreed before any attempt to build national databases. This is not yet achieved. Starting databases on a national basis can create an irreversible state where no international comparison will be possible. For instance, the way the bioeconomy is defined can vary greatly. The USA and OECD consider the bioeconomy across a variety of applications such as health, agriculture, industrial applications, marine biotechnologies i.e the potential impacts of life sciences and engineering on the whole economy in the coming decades ( a possible future industrial revolution ?). The European Commission has adopted a different definition. Industrial associations, even in Europe have a third vision.
This situation will jeopardize not only potential discussions or negotiations in international fora (on tariffs, norms, regulations, subsidies..), but also the creation of an international level playing field between actors as well as issues for potential investors to assess the potential markets.. In the previous 50 years, OECD has promoted international databases on the ground of pioneering efforts by a number of initial “champions” which create the initial definitions that other countries will later adopt.
The three main segments of statistics that OECD member countries like to encompass are linked with the life cycle of markets: readiness, intensity and impacts (figure 1). Readiness is covering the initial steps that an emerging market will come across: governments budgets, R&D expenditures, human capital, intellectual property, Intensity is devoted to activities and outputs of the industrial bioeconomy: manufacturing, assets, market share, services. Impacts deal with socio-economic dimensions or environmental dimensions, sustainability, productivity gains, net job creations.
In order to cover the ground, a number of technicalities or challenges have to be met. To name a few: issues of confidentiality are very important since the sector is competitive, reliability and comparability of databases over time or across countries has to be secured, archiving the data, and maintaining integrity of the data need financing efforts at national office of statistics or provided to other hosts..
Examples can be discussed during the session about the case of the emerging industrial bioeconomy or other sectors covered by the OECD.